This data is for laboratory research purposes only. Not for human or animal consumption.
What is Amycretin?
Amycretin (NNC0385-0434; also called zenagamtide in later-stage development) is a first-in-class, unimolecular GLP-1 and amylin receptor dual agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination of two separate molecules — cagrilintide and semaglutide), amycretin is a single molecule designed to activate both the GLP-1 receptor and the amylin/calcitonin receptor simultaneously. It is under investigation for once-weekly subcutaneous and once-daily oral administration.
Mechanism of Action
Amycretin exploits the complementary and synergistic satiety pathways of two hormones:
- GLP-1 receptor activation: Suppresses appetite via the hypothalamus and brainstem, slows gastric emptying, and enhances glucose-dependent insulin secretion.
- Amylin receptor activation: Acts on the area postrema and brainstem to reduce meal size, slow gastric emptying, and suppress glucagon. Amylin works through different neural circuits than GLP-1, providing additive satiety signalling.
The dual agonism in a single molecule simplifies dosing and may achieve greater weight loss than GLP-1 monotherapy.
Observed Clinical Results
- Phase 1b/2 (Lancet, December 2024): Subcutaneous amycretin 2.4 mg achieved ~22% mean body weight reduction vs ~10.6% with semaglutide 2.4 mg at 26 weeks in adults with obesity or overweight.
- Phase 2 T2D (NCT06542874): Zenagamtide 40 mg SC once-weekly produced 14.6% weight loss and 89.1% of patients achieving A1C <7% at 36 weeks (ADA 2026 presentation).
- Oral formulation Phase 1: ~13.1% weight loss at 12 weeks with oral amycretin in early-phase data.
- Phase 3 REDEFINE obesity programme: Enrolling as of Q1 2026.
Regulatory Status
Currently Investigational — no regulatory approval as of June 2026. Phase 3 obesity programme initiated Q1 2026; Phase 3 for type 2 diabetes planned H2 2026. No compounding eligibility.